Search hospitals > Manitoba > WINNIPEG
St. Boniface General Hospital
Claim this profileWINNIPEG, Manitoba R2H 2A6
Global Leader in Heart Failure
Global Leader in Heart Attack
Conducts research for Post-Heart Attack Syndrome
Conducts research for Cardiovascular Disease
Conducts research for Bleeding
147 reported clinical trials
14 medical researchers
Summary
St. Boniface General Hospital is a medical facility located in WINNIPEG, Manitoba. This center is recognized for care of Heart Failure, Heart Attack, Post-Heart Attack Syndrome, Cardiovascular Disease, Bleeding and other specialties. St. Boniface General Hospital is involved with conducting 147 clinical trials across 236 conditions. There are 14 research doctors associated with this hospital, such as Ashish B. Shah, M.D., Ryan Zarychanski, MD, Thang Nguyen, MD, and Michael Yamashita, MD.Top PIs
Ashish B. Shah, M.D.Vanderbilt University Medical Center4 years of reported clinical research
Studies Brain Tumor
Studies Subtalar Arthritis
11 reported clinical trials
14 drugs studied
Ryan Zarychanski, MDSt. Boniface Hospital3 years of reported clinical research
Studies Gastrointestinal Bleeding
Studies Postoperative Bleeding
5 reported clinical trials
65 drugs studied
Thang Nguyen, MDSt. Boniface Hospital6 years of reported clinical research
Studies Breast Cancer
Studies Cardiovascular Disease
2 reported clinical trials
3 drugs studied
Michael Yamashita, MDUniversity of Manitoba7 years of reported clinical research
Studies Thoracic Aortic Disease
Studies Bleeding
2 reported clinical trials
3 drugs studied
Clinical Trials running at St. Boniface General Hospital
Heart Attack
Post-Heart Attack Syndrome
Cardiotoxicity
Frailty
Coronary Artery Disease
Heart Disease
Malnutrition
Staphylococcus aureus Infections
Catheter-Associated Bacteremia
Staph Bacteremia
Post-Discharge Care
for Heart Attack
This randomized control trial seeks to better understand the educational needs of Acute Coronary Symptom (ACS) patients including the optimal timing and method of delivery as well as linkages with appropriate community resources and supports are important for cardiac patients to self-manage post hospital discharge to improve outcomes. While there is some literature of the learning needs of ACS patients, there is a paucity of research related to the timing and preferred methods of delivery. This study aims to better understand how best to tailor care for ACS patients from hospital to community. Specifically, the investigators propose a 2 phased approach to understand the needs of patients, and then to develop and deliver a tailored approach to assess, educate and support patients both in-hospital and within the community. The intervention compares 1) a virtual remote home monitoring (RHM) platform and 2) Rapid Response Nursing (RRN) staff to follow, educate and support ACS patients post hospital discharge for a period of no more than 30 days. The Primary Objective of this study is to safely transition low risk ACS patients, from hospital to home, with appropriate supports to safely self-manage in the community and to provide educational and community supports to improve post discharge outcomes of low risk ACS patients
Recruiting1 award N/A2 criteria
Ziltivekimab
for Heart Attack
The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant will need to inject the study medicine into a flat skin surface in there stomach, thigh, or upper arm once every month. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.
Recruiting1 award Phase 35 criteria
BI 765845
for Heart Attack
This study is open to adults aged 18 and over who have just had a heart attack. The purpose of this study is to find out whether a medicine called BI 765845 helps people who have had a heart attack. The investigators also want to test how well different doses of BI 765845 work and how they are tolerated by people who have had a heart attack. Participants are randomly assigned to receive either BI 765845 or placebo. Placebo treatments look like BI 765845 treatments but do not contain any medicine. Participants are about 3 times as likely to receive BI 765845 than placebo. Participants are in the study for 3 months. During this time, they visit the study site 7 times and get 3 phone calls from the site staff. At the visits, the doctors use clinical tests to check the health of the heart. The results are compared between the BI 765845 and placebo groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Recruiting0 awards Phase 2
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at St. Boniface General Hospital?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.